Sign In
Buy MNPR
$60.56
-0.700 (-1.14%)
At Close: Jun 03, 2026
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
11:07am, Thursday, 02'nd Jan 2025
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
11:32am, Thursday, 26'th Dec 2024
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
02:23pm, Monday, 23'rd Dec 2024
MNPR-101-Lu is being developed in a phase 1 study to target advanced solid tumor patients with uPAR expression. MNPR-101-Zr is being used as an imaging agent to determine which advanced solid tumor pa
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
04:21pm, Thursday, 05'th Dec 2024
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet m
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
08:00am, Tuesday, 03'rd Dec 2024
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet m
3 Momentum Stocks Soaring Into 2025 and Beyond
07:01am, Tuesday, 03'rd Dec 2024
Investors favoring a short horizon and possessing a fair amount of risk tolerance sometimes look to stocks that have already been trending upward in an effort to capitalize on their momentum. This inv
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'
02:25pm, Monday, 02'nd Dec 2024
Monopar Therapeutics (MNPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed t
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'
02:25pm, Monday, 02'nd Dec 2024
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus
07:53pm, Monday, 25'th Nov 2024
Monopar Therapeutics is a clinical-stage biotech focused on radiopharmaceuticals for oncology and recently expanded into rare diseases with ALXN-1840. MNPR's oncology pipeline includes MNPR-101-Zr for
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
08:00am, Friday, 08'th Nov 2024
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Ca
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
01:42pm, Wednesday, 30'th Oct 2024
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developi
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
09:15pm, Monday, 28'th Oct 2024
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developi
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
04:00pm, Monday, 28'th Oct 2024
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developi
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?
01:29pm, Monday, 28'th Oct 2024
The stock price of Monopar Therapeutics (NASDAQ: MNPR), a clinical-stage biopharmaceutical company, skyrocketed from levels of $5.25 on Monday, October 21, to $32.66 on Thursday, October 24, before fa
